Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study: Basel Wednesday, December 10, 2025, 18:00 Hrs [IST] Roch ...

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

Basel, 8 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment lines for people living with different ...

The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...

The FDA has started a priority review of BeOne Medicines' BCL2 inhibitor sonrotoclax in relapsed or refractory mantle cell lymphoma (MCL), setting up a decision on US approval next year. Sonrotoclax ...

Roche’s move into the digital pathology category has been boosted by FDA approval of a lab instrument and toolkit for use as an aid to clinical diagnosis. The clearance covers Roche’s Ventana DP 200 ...

Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...

Weight-loss drug developers line up to tap lucrative market as competition heats up The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as ...

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as ...